NCT06380751 2026-04-14
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
Clinical Trials
8 trialsNCT05753865 2023-03-03
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT03538171 2021-07-09
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
Phase 3 Unknown
NCT03927456 2021-06-03
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03966898 2021-06-02
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02054338 2019-08-28
VICTORIA
Pierre Fabre Medicament
Phase 3 Terminated
NCT00327769 2011-01-25
Faslodex Advanced Breast Cancer Local Chinese Study
AstraZeneca
Phase 3 Completed
NCT00635713 2009-04-10
Second Line Breast Cancer Trial
AstraZeneca
Phase 3 Completed